Cargando…

Detection of HER2 amplification in circulating free DNA in patients with breast cancer

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in 20–25% of breast cancers. This study investigated circulating free DNA (cfDNA) for detection of HER2 gene amplification in patients with breast cancer. METHODS: Circulating free DNA was extracted from plasm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Page, K, Hava, N, Ward, B, Brown, J, Guttery, D S, Ruangpratheep, C, Blighe, K, Sharma, A, Walker, R A, Coombes, R C, Shaw, J A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078598/ https://www.ncbi.nlm.nih.gov/pubmed/21427727 http://dx.doi.org/10.1038/bjc.2011.89

Ejemplares similares

The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy
por: Payne, R E, et al.
Publicado: (2012)

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer
por: Flores, L M, et al.
Publicado: (2010)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma
por: Mimura, K, et al.
Publicado: (2005)

Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients
por: Payne, R E, et al.
Publicado: (2012)

Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification
por: Betof, A S, et al.
Publicado: (2012)

Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment
por: Slade, M J, et al.
Publicado: (2009)

Circulating cell-free miRNAs as biomarker for triple-negative breast cancer
por: Shin, V Y, et al.
Publicado: (2015)

PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas
por: Aubele, M, et al.
Publicado: (2007)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma
por: Greystoke, A, et al.
Publicado: (2011)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer
por: Ettl, T, et al.
Publicado: (2012)

Interleukin-6 gene amplification and shortened survival in glioblastoma patients
por: Tchirkov, A, et al.
Publicado: (2007)

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
por: Pils, D, et al.
Publicado: (2007)

Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity
por: Wilson, G R, et al.
Publicado: (2006)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer
por: Zhu, C-Q, et al.
Publicado: (2006)

Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers
por: Takahashi, Y, et al.
Publicado: (2014)

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer
por: Ihnen, M, et al.
Publicado: (2010)

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes
por: Shapira, I, et al.
Publicado: (2014)

A positive role for PEA3 in HER2-mediated breast tumour progression
por: Myers, E, et al.
Publicado: (2006)

FGFR2 gene amplification and clinicopathological features in gastric cancer
por: Matsumoto, K, et al.
Publicado: (2012)

Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma
por: Takeshita, H, et al.
Publicado: (2010)

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches
por: Lehmann-Che, J, et al.
Publicado: (2011)

Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma
por: Tokuhisa, Y, et al.
Publicado: (2007)

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype
por: Ameri, K, et al.
Publicado: (2010)

Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma
por: Teng, M, et al.
Publicado: (2014)

Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer
por: Cihoric, N, et al.
Publicado: (2014)

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer
por: Ankeny, J S, et al.
Publicado: (2016)

A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk
por: Katz, E, et al.
Publicado: (2010)

Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide
por: Young, R J, et al.
Publicado: (2012)

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
por: Zidan, J, et al.
Publicado: (2005)

Circulating microRNAs in plasma of patients with gastric cancers
por: Tsujiura, M, et al.
Publicado: (2010)

Levels of a subpopulation of platelets, but not circulating endothelial cells, predict early treatment failure in prostate cancer patients after prostatectomy
por: Wong, C K E, et al.
Publicado: (2012)

Changes in circulating microRNA levels associated with prostate cancer
por: Bryant, R J, et al.
Publicado: (2012)

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study
por: Su, X, et al.
Publicado: (2014)

ANO1 amplification and expression in HNSCC with a high propensity for future distant metastasis and its functions in HNSCC cell lines
por: Ayoub, C, et al.
Publicado: (2010)

MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells
por: Ponnusamy, M P, et al.
Publicado: (2008)

Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases
por: Joosse, S A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k5jrfv9i5stupl16q1jh5micsb